[go: up one dir, main page]

BR9808591A - Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis. - Google Patents

Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis.

Info

Publication number
BR9808591A
BR9808591A BR9808591-3A BR9808591A BR9808591A BR 9808591 A BR9808591 A BR 9808591A BR 9808591 A BR9808591 A BR 9808591A BR 9808591 A BR9808591 A BR 9808591A
Authority
BR
Brazil
Prior art keywords
treatment
matrix protein
rheumatoid arthritis
oligomeric matrix
cartilage oligomeric
Prior art date
Application number
BR9808591-3A
Other languages
Portuguese (pt)
Inventor
Dick Heinegard
Johnny Lorentzen
Lars Klareskog
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of BR9808591A publication Critical patent/BR9808591A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"USO DE PROTEìNA DE MATRIZ OLIGOMéRICA DE CARTILAGEM PARA O TRATAMENTO DE ARTRITE REUMATóIDE"<D>. A invenção se refere ao uso de uma proteína de matriz oligomérica de cartilagem (COMP) ou fragmentos ou análogos da mesma, para a fabricação de uma composição farmacêutica para a prevenção ou tratamento de condições artríticas, em que a composição farmacêutica é administrada em uma quantidade eficaz, de modo a evitar ou tratar a condição artrítica.<B> "USE OF OLIGOMERIC CARTILAGE MATRIX PROTEIN FOR THE TREATMENT OF RHEUMATOID ARTHRITIS" <D>. The invention relates to the use of a cartilage matrix protein (COMP) or fragments or analogues thereof, for the manufacture of a pharmaceutical composition for the prevention or treatment of arthritic conditions, in which the pharmaceutical composition is administered in an amount effective in order to avoid or treat the arthritic condition.

BR9808591-3A 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis. BR9808591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701409A SE9701409D0 (en) 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis
PCT/SE1998/000682 WO1998046253A1 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
BR9808591A true BR9808591A (en) 2000-05-23

Family

ID=20406587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808591-3A BR9808591A (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis.

Country Status (21)

Country Link
EP (1) EP1019078B1 (en)
JP (1) JP2001520647A (en)
KR (1) KR20010006352A (en)
CN (1) CN1260721A (en)
AT (1) ATE245438T1 (en)
AU (1) AU746221B2 (en)
BR (1) BR9808591A (en)
CA (1) CA2286791A1 (en)
DE (1) DE69816634T2 (en)
EE (1) EE9900464A (en)
HU (1) HUP0002231A3 (en)
ID (1) ID24561A (en)
IL (1) IL132354A0 (en)
IS (1) IS5210A (en)
NO (1) NO995004D0 (en)
NZ (1) NZ338084A (en)
PL (1) PL336163A1 (en)
SE (1) SE9701409D0 (en)
SK (1) SK141399A3 (en)
TR (1) TR199902564T2 (en)
WO (1) WO1998046253A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849594B1 (en) * 1999-06-30 2005-02-01 John Lawler Purification and use of human recombinant cartilage oligomeric matrix protein
SE9904236D0 (en) 1999-11-22 1999-11-22 Ana Mar Diagnostics Ab Immunoassay
KR100429288B1 (en) * 2001-11-23 2004-04-29 장오기계 주식회사 Device for decalcomania printing
CN100417415C (en) * 2006-06-28 2008-09-10 文彦春 Infiltration Drugs for Arthritis
WO2014003679A1 (en) 2012-06-28 2014-01-03 Anamar Ab Determining pathological cartilage turnover

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5872094A (en) * 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface

Also Published As

Publication number Publication date
DE69816634D1 (en) 2003-08-28
HUP0002231A2 (en) 2000-11-28
KR20010006352A (en) 2001-01-26
ID24561A (en) 2000-07-27
CN1260721A (en) 2000-07-19
SK141399A3 (en) 2000-08-14
DE69816634T2 (en) 2004-06-03
IL132354A0 (en) 2001-03-19
EP1019078A1 (en) 2000-07-19
JP2001520647A (en) 2001-10-30
NO995004L (en) 1999-10-14
ATE245438T1 (en) 2003-08-15
CA2286791A1 (en) 1998-10-22
IS5210A (en) 1999-10-12
EE9900464A (en) 2000-04-17
PL336163A1 (en) 2000-06-05
HUP0002231A3 (en) 2002-09-30
AU7093898A (en) 1998-11-11
WO1998046253A1 (en) 1998-10-22
TR199902564T2 (en) 2000-02-21
EP1019078B1 (en) 2003-07-23
NZ338084A (en) 2001-07-27
NO995004D0 (en) 1999-10-14
AU746221B2 (en) 2002-04-18
SE9701409D0 (en) 1997-04-15

Similar Documents

Publication Publication Date Title
BR9813154A (en) Cellulosic fiber composites
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
BR0215240A (en) Calcium derivatives and their use in treating diseases
BR0108600A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease
BR9714155A (en) Prevention of bone mass loss and replacement by certain prostaglandin agonists.
BR0111562A (en) Glucagon-like peptide 1 analogs
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
BR9808812A (en) Composition comprising crystalline, finely divided budesonide particles
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
HUP9700603A1 (en) Medicinal preparation for the treatment of blood clotting disorders
BR9806145A (en) Process for selective derivatization of taxanes
BR9813028A (en) Prostaglandin agonists and their use to treat bone disorders
BR9610872A (en) Moraxella Transferrin Receptor Protein
BR9713147A (en) Benzamidoaldehyde, use of it, benzamide, and drug preparation for oral, parenteral or intraperitoneal administration.
BRPI0109131B8 (en) dna, expression vector comprising the same, modified porcine factor viii, its production process and therapeutic composition comprising the same
BR0112685A (en) Nutritional Composition
BR9811099A (en) Urokinase inhibitors
BR9809951A (en) Method for treating obesity
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
BR9910445A (en) Pharmaceutical preparation
BR9810703A (en) Pharmaceutical composition, and processes for preparing it, and for treating a platelet aggregation disorder
FI962685A7 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the preparation of a medicament for the treatment and prevention of bone loss and osteoporosis
BR9813996A (en) 2-arylbenzo [b] thiophenes useful for the treatment of estrogen deprivation syndrome
BR9808591A (en) Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis.
BR9814945A (en) Use of phanquinone for the treatment of alzheimer&#39;s disease, pharmaceutical composition and kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1892 DE 10/04/2007.